U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...

Pfizer’s chief executive Albert Bourla decamped with his top management team to Donald Trump’s Mar-a-Lago resort for an off-site meeting, in the latest attempt by corporate Am ...

Pfizer's stock has plummeted due to declining ... or with the discontinuation of its weight loss pill. Finally, some political pressure on the vaccine segment added recently.

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

after scrapping a twice- daily version of the drug late last year. Pfizer moves forward with once-daily weight-loss pill Future of Healthcategory· July 11, 2024 U.S. President Joe Biden and ...